Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Monopar Therapeutics Inc. (NASDAQ:MNPR) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $122.78.

Several analysts have recently weighed in on the company. Cantor Fitzgerald downgraded Monopar Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the company from $109.00 to $119.00 in a report on Thursday, August 13th. Barclays restated an “overweight” rating and set a $145.00 price target (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th. BTIG Research lifted their price target on Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Wall Street Zen cut Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 10th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $130.00 price objective on shares of Monopar Therapeutics in a report on Monday, August 17th.

Monopar Therapeutics Stock Up 3.3%

NASDAQ:MNPR opened at $73.75 on Thursday. Monopar Therapeutics has a 52 week low of $50.07 and a 52 week high of $124.82. The stock has a market capitalization of $494.86 million, a PE ratio of -33.99 and a beta of 1.62. The stock’s 50-day moving average price is $86.12 and its 200-day moving average price is $77.41.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. Sell-side analysts expect that Monopar Therapeutics will post -2.98 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Monopar Therapeutics news, Director Raymond Anderson sold 3,142 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $68.35, for a total value of $214,755.70. Following the transaction, the director directly owned 5,373 shares in the company, valued at approximately $367,244.55. This represents a 36.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chandler Robinson sold 29,056 shares of the company’s stock in a transaction dated Thursday, September 24th. The shares were sold at an average price of $88.00, for a total transaction of $2,556,928.00. Following the completion of the transaction, the chief executive officer owned 99,267 shares in the company, valued at approximately $8,735,496. This trade represents a 22.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 51,920 shares of company stock worth $4,527,913 in the last ninety days. 9.70% of the stock is currently owned by insiders.

Institutional Trading of Monopar Therapeutics

Hedge funds have recently bought and sold shares of the company. Siren L.L.C. lifted its stake in shares of Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after acquiring an additional 57,820 shares in the last quarter. ADAR1 Capital Management LLC grew its position in shares of Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after buying an additional 30,370 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Monopar Therapeutics by 21.2% in the first quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company’s stock worth $4,307,000 after buying an additional 13,761 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of Monopar Therapeutics in the first quarter worth $3,458,000. Finally, Bank of America Corp DE increased its stake in shares of Monopar Therapeutics by 838.2% in the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after buying an additional 53,336 shares during the last quarter. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.